TXNIP regulates peripheral glucose metabolism in humans

Hemang Parikh, Emma Carlsson, William A. Chutkow, Lovisa E. Johansson, Heidi Storgaard, Pernille Poulsen, Richa Saxena, Christine Marie Ladd-Acosta, P. Christian Schulze, Michael J. Mazzini, Christine Bjørn Jensen, Anna Krook, Marie Björnholm, Hans Tornqvist, Juleen R. Zierath, Martin Ridderstråle, David Altshuler, Richard T. Lee, Allan Vaag, Leif C. Groop & 1 others Vamsi K. Mootha

Research output: Contribution to journalArticle

Abstract

Background: Type 2 diabetes mellitus (T2DM) is characterized by defects in insulin secretion and action. Impaired glucose uptake in skeletal muscle is believed to be one of the earliest features in the natural history of T2DM, although underlying mechanisms remain obscure. Methods and Findings: We combined human insulin/glucose clamp physiological studies with genome-wide expression profiling to identify thioredoxin interacting protein (TXNIP) as a gene whose expression is powerfully suppressed by insulin yet stimulated by glucose. In healthy individuals, its expression was inversely correlated to total body measures of glucose uptake. Forced expression of TXNIP in cultured adipocytes significantly reduced glucose uptake, while silencing with RNA interference in adipocytes and in skeletal muscle enhanced glucose uptake, confirming that the gene product is also a regulator of glucose uptake. TXNIP expression is consistently elevated in the muscle of prediabetics and diabetics, although in a panel of 4,450 Scandinavian individuals, we found no evidence for association between common genetic variation in the TXNIP gene and T2DM. Conclusions: TXNIP regulates both insulin-dependent and insulin-independent pathways of glucose uptake in human skeletal muscle. Combined with recent studies that have implicated TXNIP in pancreatic β-cell glucose toxicity, our data suggest that TXNIP might play a key role in defective glucose homeostasis preceding overt T2DM.

Original languageEnglish (US)
Pages (from-to)868-879
Number of pages12
JournalPLoS Medicine
Volume4
Issue number5
DOIs
StatePublished - May 2007
Externally publishedYes

Fingerprint

Thioredoxins
Glucose
Type 2 Diabetes Mellitus
Proteins
Insulin
Skeletal Muscle
Adipocytes
Body Weights and Measures
Glucose Clamp Technique
RNA Interference
Homeostasis
Genome
Gene Expression
Muscles

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Parikh, H., Carlsson, E., Chutkow, W. A., Johansson, L. E., Storgaard, H., Poulsen, P., ... Mootha, V. K. (2007). TXNIP regulates peripheral glucose metabolism in humans. PLoS Medicine, 4(5), 868-879. https://doi.org/10.1371/journal.pmed.0040158

TXNIP regulates peripheral glucose metabolism in humans. / Parikh, Hemang; Carlsson, Emma; Chutkow, William A.; Johansson, Lovisa E.; Storgaard, Heidi; Poulsen, Pernille; Saxena, Richa; Ladd-Acosta, Christine Marie; Schulze, P. Christian; Mazzini, Michael J.; Jensen, Christine Bjørn; Krook, Anna; Björnholm, Marie; Tornqvist, Hans; Zierath, Juleen R.; Ridderstråle, Martin; Altshuler, David; Lee, Richard T.; Vaag, Allan; Groop, Leif C.; Mootha, Vamsi K.

In: PLoS Medicine, Vol. 4, No. 5, 05.2007, p. 868-879.

Research output: Contribution to journalArticle

Parikh, H, Carlsson, E, Chutkow, WA, Johansson, LE, Storgaard, H, Poulsen, P, Saxena, R, Ladd-Acosta, CM, Schulze, PC, Mazzini, MJ, Jensen, CB, Krook, A, Björnholm, M, Tornqvist, H, Zierath, JR, Ridderstråle, M, Altshuler, D, Lee, RT, Vaag, A, Groop, LC & Mootha, VK 2007, 'TXNIP regulates peripheral glucose metabolism in humans', PLoS Medicine, vol. 4, no. 5, pp. 868-879. https://doi.org/10.1371/journal.pmed.0040158
Parikh H, Carlsson E, Chutkow WA, Johansson LE, Storgaard H, Poulsen P et al. TXNIP regulates peripheral glucose metabolism in humans. PLoS Medicine. 2007 May;4(5):868-879. https://doi.org/10.1371/journal.pmed.0040158
Parikh, Hemang ; Carlsson, Emma ; Chutkow, William A. ; Johansson, Lovisa E. ; Storgaard, Heidi ; Poulsen, Pernille ; Saxena, Richa ; Ladd-Acosta, Christine Marie ; Schulze, P. Christian ; Mazzini, Michael J. ; Jensen, Christine Bjørn ; Krook, Anna ; Björnholm, Marie ; Tornqvist, Hans ; Zierath, Juleen R. ; Ridderstråle, Martin ; Altshuler, David ; Lee, Richard T. ; Vaag, Allan ; Groop, Leif C. ; Mootha, Vamsi K. / TXNIP regulates peripheral glucose metabolism in humans. In: PLoS Medicine. 2007 ; Vol. 4, No. 5. pp. 868-879.
@article{27d50d842547496e81269cc26a49d9f8,
title = "TXNIP regulates peripheral glucose metabolism in humans",
abstract = "Background: Type 2 diabetes mellitus (T2DM) is characterized by defects in insulin secretion and action. Impaired glucose uptake in skeletal muscle is believed to be one of the earliest features in the natural history of T2DM, although underlying mechanisms remain obscure. Methods and Findings: We combined human insulin/glucose clamp physiological studies with genome-wide expression profiling to identify thioredoxin interacting protein (TXNIP) as a gene whose expression is powerfully suppressed by insulin yet stimulated by glucose. In healthy individuals, its expression was inversely correlated to total body measures of glucose uptake. Forced expression of TXNIP in cultured adipocytes significantly reduced glucose uptake, while silencing with RNA interference in adipocytes and in skeletal muscle enhanced glucose uptake, confirming that the gene product is also a regulator of glucose uptake. TXNIP expression is consistently elevated in the muscle of prediabetics and diabetics, although in a panel of 4,450 Scandinavian individuals, we found no evidence for association between common genetic variation in the TXNIP gene and T2DM. Conclusions: TXNIP regulates both insulin-dependent and insulin-independent pathways of glucose uptake in human skeletal muscle. Combined with recent studies that have implicated TXNIP in pancreatic β-cell glucose toxicity, our data suggest that TXNIP might play a key role in defective glucose homeostasis preceding overt T2DM.",
author = "Hemang Parikh and Emma Carlsson and Chutkow, {William A.} and Johansson, {Lovisa E.} and Heidi Storgaard and Pernille Poulsen and Richa Saxena and Ladd-Acosta, {Christine Marie} and Schulze, {P. Christian} and Mazzini, {Michael J.} and Jensen, {Christine Bj{\o}rn} and Anna Krook and Marie Bj{\"o}rnholm and Hans Tornqvist and Zierath, {Juleen R.} and Martin Ridderstr{\aa}le and David Altshuler and Lee, {Richard T.} and Allan Vaag and Groop, {Leif C.} and Mootha, {Vamsi K.}",
year = "2007",
month = "5",
doi = "10.1371/journal.pmed.0040158",
language = "English (US)",
volume = "4",
pages = "868--879",
journal = "Nature Clinical Practice Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - TXNIP regulates peripheral glucose metabolism in humans

AU - Parikh, Hemang

AU - Carlsson, Emma

AU - Chutkow, William A.

AU - Johansson, Lovisa E.

AU - Storgaard, Heidi

AU - Poulsen, Pernille

AU - Saxena, Richa

AU - Ladd-Acosta, Christine Marie

AU - Schulze, P. Christian

AU - Mazzini, Michael J.

AU - Jensen, Christine Bjørn

AU - Krook, Anna

AU - Björnholm, Marie

AU - Tornqvist, Hans

AU - Zierath, Juleen R.

AU - Ridderstråle, Martin

AU - Altshuler, David

AU - Lee, Richard T.

AU - Vaag, Allan

AU - Groop, Leif C.

AU - Mootha, Vamsi K.

PY - 2007/5

Y1 - 2007/5

N2 - Background: Type 2 diabetes mellitus (T2DM) is characterized by defects in insulin secretion and action. Impaired glucose uptake in skeletal muscle is believed to be one of the earliest features in the natural history of T2DM, although underlying mechanisms remain obscure. Methods and Findings: We combined human insulin/glucose clamp physiological studies with genome-wide expression profiling to identify thioredoxin interacting protein (TXNIP) as a gene whose expression is powerfully suppressed by insulin yet stimulated by glucose. In healthy individuals, its expression was inversely correlated to total body measures of glucose uptake. Forced expression of TXNIP in cultured adipocytes significantly reduced glucose uptake, while silencing with RNA interference in adipocytes and in skeletal muscle enhanced glucose uptake, confirming that the gene product is also a regulator of glucose uptake. TXNIP expression is consistently elevated in the muscle of prediabetics and diabetics, although in a panel of 4,450 Scandinavian individuals, we found no evidence for association between common genetic variation in the TXNIP gene and T2DM. Conclusions: TXNIP regulates both insulin-dependent and insulin-independent pathways of glucose uptake in human skeletal muscle. Combined with recent studies that have implicated TXNIP in pancreatic β-cell glucose toxicity, our data suggest that TXNIP might play a key role in defective glucose homeostasis preceding overt T2DM.

AB - Background: Type 2 diabetes mellitus (T2DM) is characterized by defects in insulin secretion and action. Impaired glucose uptake in skeletal muscle is believed to be one of the earliest features in the natural history of T2DM, although underlying mechanisms remain obscure. Methods and Findings: We combined human insulin/glucose clamp physiological studies with genome-wide expression profiling to identify thioredoxin interacting protein (TXNIP) as a gene whose expression is powerfully suppressed by insulin yet stimulated by glucose. In healthy individuals, its expression was inversely correlated to total body measures of glucose uptake. Forced expression of TXNIP in cultured adipocytes significantly reduced glucose uptake, while silencing with RNA interference in adipocytes and in skeletal muscle enhanced glucose uptake, confirming that the gene product is also a regulator of glucose uptake. TXNIP expression is consistently elevated in the muscle of prediabetics and diabetics, although in a panel of 4,450 Scandinavian individuals, we found no evidence for association between common genetic variation in the TXNIP gene and T2DM. Conclusions: TXNIP regulates both insulin-dependent and insulin-independent pathways of glucose uptake in human skeletal muscle. Combined with recent studies that have implicated TXNIP in pancreatic β-cell glucose toxicity, our data suggest that TXNIP might play a key role in defective glucose homeostasis preceding overt T2DM.

UR - http://www.scopus.com/inward/record.url?scp=34249660144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249660144&partnerID=8YFLogxK

U2 - 10.1371/journal.pmed.0040158

DO - 10.1371/journal.pmed.0040158

M3 - Article

VL - 4

SP - 868

EP - 879

JO - Nature Clinical Practice Oncology

JF - Nature Clinical Practice Oncology

SN - 1759-4774

IS - 5

ER -